Brief: Oncopeptides Says Research Shows Pepaxti Effective In High-Risk Myeloma
29/12/2025 09:51
Dec 29 (Reuters) - Oncopeptides AB ONCO.ST: SAYS RESEARCH SHOWS THAT PEPAXTI IS EFFECTIVE IN HIGH-RISK MYELOMA RESEARCH SUPPORTS EARLIER OBSERVATIONS FROM PHASE 3 OCEAN STUDY Source text: ID:nMFN1jm5Pr Further company coverage: ONCO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy